As the strategy gets unveiled here, it’s becoming obvious the LC is a genius when it comes to trial strategy.
Couldn't have put it better myself TB, but apparently it's not so obvious to many posters. Clinical studies can serve multiple purposes, if you have the cash to run them. Off-label use is massive in oncology, especially given the wealth of options precently available to Drs. If the patient can pay, has few alternatives and is close to the end, they'll shoot up most anything that looks pomising!
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-101
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |